Over 1.8 million nonprofits and charities for donors, volunteers and funders

2016 Top-Rated Nonprofit

Multidisciplinary Association For Psychedelic Studies

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Volunteering Oportunities

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

170 Stories from Volunteers, Donors & Supporters

4

Donor

Rating: 5

MAPS is an incredible organization working towards a very noble and important cause - to bring the therapeutic benefits of psychedelics into the limelight so millions of patients all over the world can benefit from new treatments. They are the only charity I have come across that is working towards this goal. My experiences with MAPS have all been positive, I wholly support their work and would encourage anyone think of supporting them to do so.

4

Donor

Rating: 5

I have been tracking MAPS since shortly before its inception - about 25 years. Astonishingly, MAPS met its ambitious agenda, bridging scientific, social, legal and political hurdles that had hampered researchers for most of a century.

Review from Guidestar

4

Donor

Rating: 4

The MAPS Psychedelic Science Conference in 2010 was a landmark, watershed event, bringing together some great minds and scientists, and the community in general. MAPS is leading the way in a renewal of psychedelic studies, in terms of chemistry, pharmacology, neuroscience, psychology and more, a renewal that is likely to have far-reaching consequences for modern science and society as a whole.

4

Donor

Rating: 5

MAPS is in a crucial position to make the change in the minds of humanity that must happen for our species to have a future. There is a famous quote by Einstein that goes something like "problems can not be solved by the same minds that created them". This speaks to the necessity of MAPS work to validly research and document the potential of psychoactive medications to positively impact our psychological wellbeing and cognitive potential. A few hours ago I treated in my ED a young veteran suffering from debilitating PTSD. I wish that he and so many others of his peers had access to the incredible treatments that MAPS studies have demonstrated under research conditions.

4

Donor

Rating: 5

Since my discovery of psychedelics about 5 years ago, my life has turned around. I feel more happy about myself, I feel I am a human spiritual being, very connected to everything around me. Psychedelics have taught me to open my heart a bit more. What made me sad is that these same psychedelics are being misused and therefore get a bad reputation. MAPS is doing valuable work in getting psychedelics the right reputation: as medicine and a tool to gain more knowledge about yourself and the divine.

Review from Guidestar

4

Donor

Rating: 5

I have been a supporter of MAPS for over five years and have always been pleased with their courage and their ability to break new and valuable ground. They are determined and inspired working in such a complex field. The funds they receive are thoughtfully applied to their projects. Rick is man of great integrity, intelligence and humility. I am grateful that they continue to be sucessful in thier ground breaking work.

Review from Guidestar

4

Donor

Rating: 5

The insights I received from my experience with psychedelic substances more than forty years ago revealed a great deal about my mind that had previously been veiled in confusion. I found an inner light to guide my life, and it has been rich and rewarding as a direct result. During a peak psychedelic experience I realized that the state I was in was exactly what the ancient wise seers from all parts of the globe were talking about. In a miraculously short period of time I found an authentic descendant of those ancient seers to teach me, and have spent my life studying Vedantic psychology and using it to help others as well as myself. I consider it a major tragedy that the life-restoring medicines known as psychedelics are barred from any legal uses. As illicit substances they are much more likely to be misused than if they were legal and honored as sacred and revelatory. Naturally, when I learned of MAPS I immediately became a supporter, and have been gratified that the organization has had significant successes in the face of intractable hostility in the political arena. Thanks to their hard work, there is a decent chance that this particular tragedy may transform into triumph. The human race needs a lot of help if we are to survive as a species. MAPS is working hard to pry open an important doorway to a much more sane future. Its project is worthy of widespread support.

Review from Guidestar

4

Donor

Rating: 5

MAPS has informed me of the risks and benefits of the medical use of MDMA and from a non-biased view. I remember looking at an old Vietnam vet off the corner of a local freeway exit. The face of a life lost accompanied by its companion hopelessness. It seemed to sag down not just on his face but with his worn and sweaty clothing. The stains of dirt and blood were all products of his attempts to drink away the past. This broken man was far from over just as long as death was far from him. His gestures motioned otherwise. Obviously just a psychologist wasn't enough what else can one do when someone needs to speak but the pain is too great to speak of and how? The product of MDMA reducing the fear response widens the window of communication between a trained therapist. If this man could talk for just a few session under the influence of a doctor and MDMA, would we still see the man sitting on the street corner with nothing to live for? I am a huge advocate of medicinal psychedelic treatment.

Review from Guidestar

4

Donor

Rating: 5

M.A.P.S is doing some of the most important medical research in the world today. Their hard work and perseverance in the field of psychedelics has some of the most profound medical and psychological potential implications for not individuals but for society as a whole. I pray that they continue with their great success and succeed in breaking the negative stigma that psychedelic's have had for too long.

Review from Guidestar

4

Donor

Rating: 4

The thing I appreciate most about MAPS is that based on my perceptions (although they may be biased), MAPS has a stellar reputation in the science community. Because psychedelic research has a somewhat checkered history (although certainly no more so than any other area of psychological research), I think it is extremely important to maintian a credible reputation. MAPS covers a wide area of research, and I think that makes it even more challenging. They seem to work with top-notch scientists from all over the world and MAPS is deeply commited to this important work.

Review from Guidestar

4

Donor

Rating: 5

(Be patient with my english...I am a french-canadian...) MAPS will achieve the impossible. With Love and Compassion, Rick Doblin and his crew will litterally change the world. And I mean...YOUR WHOLE CONCEPTION OF THE REALITY. Nothing less. Why?... Simply said, because MAPS's works with psychedelic substances will lead to a paradigm shift. At the end, Truth will prevail. At the end, Truth will set us free. All of us. Thank you, MAPS, you are a lighthouse in my life. Jocelyn Blais Quebec

Review from Guidestar

6

Donor

Rating: 5

MAPS' work in designing and sponsoring research on the use of MDMA in conjunction with psychotherapy for the treatment of post-traumatic stress disorder (PTSD) is invaluable. PTSD is one of the most common mental disorders. Lifetime prevalence in the US is estimated to be around 8%. In some areas, such as south-central Los Angeles, which is heavily impacted by gang activity, up to 30% of the population is believed to currently suffer from PTSD. In order to make a significant dent into these statistics and alleviate the suffering of millions, an efficient treatment approach is needed. I believe that MAPS is on the right track here, as their treatment designs promise to deliver results within a relatively short amount of time, not requiring the years of therapy or medication that traditional approaches prescribe.

6

Donor

Rating: 5

Maintaining an evidenced based focus on exploring the clinical use of entheogens is the work of MAPS. I am a nurse with over 40 years of experience observing the pros and cons of allopathic psychotropic medicines. So many side effects leading to non-compliance leave patients still suffering. The psychedelic medicines have brought people to a place of understanding the need to feel compassion for themselves and have shown them a way to break patterns and re-structure their inner chaos. MAPS has opened minds and opened doors to a new view of those medicines that should never have been placed into Schedule I.

Review from Guidestar

4

Donor

Rating: 5

As an interested observer of developments in cognitive science and related fields, I find MAPS research to be an invaluable resource. MAPS makes a unique contribution to science and society because it boldly explores the therapeutic potential of psychedelics, which are typically neglected in medical research elsewhere. MAPS research is worthy of our support because it shines a light on the beneficial applications of substances such as MDMA that were criminalized in ignorance.

4

Donor

Rating: 5

MAPS is a world leader in funding/ publishing psychedelic research. I believe that psychedelic research will bring untold benefits a whole range of people across the globe.

4

Donor

Rating: 5

I believe MAPS is doing critical work in an underfunded area. I believe that psychedelic psychotherapy will be helpful to many people.

4

Donor

Rating: 5

Maps is a trail blazer. They scientifically research misunderstood drugs and putting them in a real context that can truly help people survive damaging events in their lives.

4

Donor

Rating: 5

Who would utilize substantial resources to research chemicals that the government has put its legal pox on? It looks like a fools errand, but the social payoff could be substantial. MAPS, that’s who, a well organized and focused organization that finances and oversees medical research in the use of psychedelics.

4

Donor

Rating: 5

MAPS research is going beyond today's traditional approaches. Psychedelic medicine is out there for real solutions for people who have not found one in conventional medicine. Psychedelic research has been overlooked for many years due to taboo of the tactics used, but is now being looked at again. MAPS purpose is to help afflicted people by any means of medicine. Their research is important in finding new, undiscovered medicine.

Review from Guidestar

4

Donor

Rating: 5

This nonprofit helps veterans to heal from the wounds of war and has the potential to help society as a whole heal from our destruction habit patterns.

Review from Guidestar